OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study
Francque Sven M., Bedossa Pierre, Abdelmalek Manal F., et al.
Contemporary Clinical Trials (2020) Vol. 98, pp. 106170-106170
Open Access | Times Cited: 60
Francque Sven M., Bedossa Pierre, Abdelmalek Manal F., et al.
Contemporary Clinical Trials (2020) Vol. 98, pp. 106170-106170
Open Access | Times Cited: 60
Showing 1-25 of 60 citing articles:
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 483
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 483
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
Samer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1809-1824
Open Access | Times Cited: 265
Samer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1809-1824
Open Access | Times Cited: 265
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Leen Heyens, Dana Busschots, Ger H. Koek, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 163
Leen Heyens, Dana Busschots, Ger H. Koek, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 163
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143
Diet and exercise in NAFLD/NASH: Beyond the obvious
Georg Semmler, Christian Datz, Thomas Reiberger, et al.
Liver International (2021) Vol. 41, Iss. 10, pp. 2249-2268
Open Access | Times Cited: 123
Georg Semmler, Christian Datz, Thomas Reiberger, et al.
Liver International (2021) Vol. 41, Iss. 10, pp. 2249-2268
Open Access | Times Cited: 123
Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
Virender Kumar, Xiaofei Xin, Jingyi Ma, et al.
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113888-113888
Open Access | Times Cited: 109
Virender Kumar, Xiaofei Xin, Jingyi Ma, et al.
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113888-113888
Open Access | Times Cited: 109
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
Andrea Boccatonda, Lorenzo Andreetto, Damiano D’Ardes, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 883-883
Open Access | Times Cited: 65
Andrea Boccatonda, Lorenzo Andreetto, Damiano D’Ardes, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 883-883
Open Access | Times Cited: 65
Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Hepatology (2023) Vol. 15, Iss. 2, pp. 180-200
Open Access | Times Cited: 45
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Hepatology (2023) Vol. 15, Iss. 2, pp. 180-200
Open Access | Times Cited: 45
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1778-1778
Open Access | Times Cited: 2
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1778-1778
Open Access | Times Cited: 2
Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
Arshi Khanam, Paul Saleeb, Shyam Kottilil
Cells (2021) Vol. 10, Iss. 5, pp. 1097-1097
Open Access | Times Cited: 84
Arshi Khanam, Paul Saleeb, Shyam Kottilil
Cells (2021) Vol. 10, Iss. 5, pp. 1097-1097
Open Access | Times Cited: 84
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Youngmin A. Lee, Scott L. Friedman
Journal of Internal Medicine (2021) Vol. 291, Iss. 1, pp. 11-31
Open Access | Times Cited: 72
Youngmin A. Lee, Scott L. Friedman
Journal of Internal Medicine (2021) Vol. 291, Iss. 1, pp. 11-31
Open Access | Times Cited: 72
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
Ting Hong, Yiyan Chen, M Kellis, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 69
Ting Hong, Yiyan Chen, M Kellis, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 69
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
Abdul M. Majzoub, Tarek Nayfeh, Abbey Barnard, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 7, pp. 880-889
Open Access | Times Cited: 68
Abdul M. Majzoub, Tarek Nayfeh, Abbey Barnard, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 7, pp. 880-889
Open Access | Times Cited: 68
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4305-4305
Open Access | Times Cited: 54
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4305-4305
Open Access | Times Cited: 54
The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities
M. V. Maevskaya, Yu. V. Kotovskaya, В. Т. Ивашкин, et al.
Terapevticheskii arkhiv (2022) Vol. 94, Iss. 2, pp. 216-253
Open Access | Times Cited: 40
M. V. Maevskaya, Yu. V. Kotovskaya, В. Т. Ивашкин, et al.
Terapevticheskii arkhiv (2022) Vol. 94, Iss. 2, pp. 216-253
Open Access | Times Cited: 40
Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
Stephen Malnick, Pavel Alin, Marina Somin, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 16226-16226
Open Access | Times Cited: 40
Stephen Malnick, Pavel Alin, Marina Somin, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 16226-16226
Open Access | Times Cited: 40
Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
S Kamata, Akihiro Honda, Isao Ishii
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1264-1264
Open Access | Times Cited: 35
S Kamata, Akihiro Honda, Isao Ishii
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1264-1264
Open Access | Times Cited: 35
Oligonucleotide therapies for nonalcoholic steatohepatitis
Sixu Li, Feng Xiong, Songbo Zhang, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 2, pp. 102184-102184
Open Access | Times Cited: 9
Sixu Li, Feng Xiong, Songbo Zhang, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 2, pp. 102184-102184
Open Access | Times Cited: 9
Targeting cell-intrinsic metabolism for antifibrotic therapy
Hélène Gilgenkrantz, Ariane Mallat, Richard Moreau, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1442-1454
Open Access | Times Cited: 44
Hélène Gilgenkrantz, Ariane Mallat, Richard Moreau, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1442-1454
Open Access | Times Cited: 44
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 32
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 32
Macrophages as key regulators of liver health and disease
Eleni Papachristoforou, Prakash Ramachandran
International review of cell and molecular biology (2022), pp. 143-212
Closed Access | Times Cited: 31
Eleni Papachristoforou, Prakash Ramachandran
International review of cell and molecular biology (2022), pp. 143-212
Closed Access | Times Cited: 31
Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines
Lijun Gong, Fang Wei, Frank J. Gonzalez, et al.
Hepatology (2023) Vol. 78, Iss. 5, pp. 1625-1653
Open Access | Times Cited: 18
Lijun Gong, Fang Wei, Frank J. Gonzalez, et al.
Hepatology (2023) Vol. 78, Iss. 5, pp. 1625-1653
Open Access | Times Cited: 18
The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease
Branka Filipović, Snežana Lukić, Dragana Mijač, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13219-13219
Open Access | Times Cited: 33
Branka Filipović, Snežana Lukić, Dragana Mijač, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13219-13219
Open Access | Times Cited: 33
Update of Indoles: Promising molecules for ameliorating metabolic diseases
Wei Hu, Guanyu Yan, Qian Ding, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112957-112957
Open Access | Times Cited: 24
Wei Hu, Guanyu Yan, Qian Ding, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112957-112957
Open Access | Times Cited: 24
Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches
Enrico Conte
Pharmacology & Therapeutics (2021) Vol. 234, pp. 108031-108031
Closed Access | Times Cited: 32
Enrico Conte
Pharmacology & Therapeutics (2021) Vol. 234, pp. 108031-108031
Closed Access | Times Cited: 32
